Uveal melanoma (UM) is a rare tumour with a high propensity to metastasize. Although no effective treatment for metastases yet exists, prognostication in UM is relevant for patient counselling, planning of follow-up and stratification in clinical trials. Besides conventional clinicopathologic characteristics, genetic tumour features with prognostic significance have been identified. Non-random chromosome aberrations such as monosomy 3 and gain of chromosome 8q are strongly correlated with metastatic risk, while gain of chromosome 6p indicates a low risk. Recently, mutations in genes such as BAP1, SF3B1 and EIF1AX have been shown to be related to patient outcome. Genetics of UM is a rapidly advancing field, which not only contributes to the understanding of the pathogenesis of this cancer, but also results in further refinement of prognostication. Concomitantly, advances have been made in the use of genetic tests. New methods for genetic typing of UM have been developed. Despite the considerable progress made recently, many questions remain, such as those relating to the reliability of prognostic genetic tests, and the use of biopsied or previously irradiated tumour tissue for prognostication by genetic testing. In this article, we review genetic prognostic indicators in UM, also comparing available genetic tests, addressing the clinical application of genetic prognostication and discussing future perspectives for improving genetic prognostication in UM.
Introduction
Uveal melanoma (UM) arises from melanocytes residing in the uveal tract, which comprises the iris, ciliary body and choroid. Uveal melanoma (UM) accounts for most (85%) ocular melanomas and is the most common primary intraocular malignancy in adults . The mean annual age-adjusted incidence in the United States is 5.1 per million, with a male-tofemale ratio of 1.1:1 (Mahendraraj et al. 2016) . The mean age at diagnosis is 61 years and most patients develop UM after the age of 50 (Mahendraraj et al. 2016) . Approximately 95% of UMs occur in Caucasians (Mahendraraj et al. 2016) , especially in those with a light iris colour, fair skin, propensity to sunburn and a tendency to develop common/atypical cutaneous nevi and cutaneous freckles (van Hees et al. 1994; Metzelaar-Blok et al. 2001; Weis et al. 2006; Nayman et al. 2017) . Oculodermal melanocytosis (nevus of Ota), which affects 0.04% of the White population (Gonder et al. 1982) , is associated with a 1 in 400 risk of UM (Singh et al. 1998) . Choroidal nevi are estimated to have a 1-in-4300 to 1-in-8845 per year risk of malignant transformation (Ganley & Comstock 1973; Sumich et al. 1998; Singh et al. 2005) . Evidence correlating ultraviolet light exposure with UM is inconclusive. Arc welding has been reported to be a risk factor (Shah et al. 2005) ; however, welding arcs are also a source of blue light, which has recently been proposed as a risk factor for the development of UM (Logan et al. 2015) .
In the last past few decades, many advances have been made in the treatment of the primary tumour, which include various forms of radiotherapy, phototherapy and local resection. These eye-sparing methods have largely replaced enucleation, which is now reserved for large UMs, tumours involving the optic nerve and eyes with a poor visual prognosis. Early detection of UM may enhance opportunities for eye-conserving therapy (Ah-Fat & Damato 1998; . Damato et al. (2014) have provided tentative evidence that early treatment of tumours may prevent metastatic disease and improve survival in patients with small tumours. However, survival of patients with metastasized UM has not improved because effective treatment for metastases is lacking. The overall 10-year metastasis rate is 40% with almost 50% of patients eventually dying from metastases, which usually involve the liver. The median survival time after the diagnosis of metastases ranges from 4 to 15 months (Augsburger et al. 2009 ).
Despite the lack of effective therapies for metastasized UM, prognostication in UM is valuable as it enables clinicians to reassure patients who have a low risk of metastasis and to target special measures at high-risk patients, who are likely to have clinically undetectable micrometastases at the time of diagnosis of the primary UM (Eskelin et al. 2000) . These patients may be included in clinical trials to determine the efficacy of adjuvant treatments for UM metastases. Moreover, reliable prognostication allows risk-based planning of screening for metastases, preventing unnecessary investigations in those with a good favourable prognosis.
Various patient and tumour characteristics have been identified as survival predictors in UM. For example, the prognosis of juveniles is better than that of adults, independently of other risk factors (Shields et al. 2012; AlJamal et al. 2016) . Clinical features corresponding to an increased metastatic risk include large tumour size, ciliary body involvement and extraocular extension (Shammas & Blodi 1977; Affeldt et al. 1980; Seddon et al. 1983; Shields et al. 2009 ). These form the basis of the Tumour, Node, Metastasis (TNM) staging system of the American Joint Committee on Cancer (AJCC) (Kujala et al. 2013 ). This prognostication system has recently been validated in large studies (AJCC Ophthalmic Oncology Task Force 2015, Shields et al. 2015) . Histopathologic predictors of metastasis include epithelioid melanoma cytomorphology (McLean et al. 1983) , high mitotic count (McLean et al. 1977) , lymphocytic infiltration (de la Cruz et al. 1990 ), extravascular matrix loops (Folberg et al. 1992 ) and vascular invasion (Ly et al. 2010) .
Early studies of the genetics of UM indicated that non-random alterations of chromosomes 3, 6 and 8 are common and have prognostic significance. Recently, molecular classification of UMs based on gene expression data has been shown to correlate with survival. Several studies have demonstrated that genetic markers have better prognostic accuracy than clinical and histopathologic biomarkers. Although considerable progress has been made in the genetic characterization of UM, questions remain with regard to the accuracy of markers, the reliability of genetic tests and the use of biopsy specimens or previously irradiated tumour tissue for prognostication by genetic testing.
In this article, we address genetic prognostic indicators in UM, compare current genetic tests, discuss genetic testing in biopsied and irradiated tumours, and propose methods for improving genetic prognostication in UM.
Genetic Prognostic Markers
Genomic instability is one of the hallmarks of cancer (Negrini et al. 2010; Shen 2011) . However, in comparison to cutaneous melanoma and other cancers, UM has relatively few mutations (Coleman et al. 1995; Papadopoulos et al. 2002; Cross et al. 2003; Ehlers et al. 2008) . In UM, one can identify recurring non-random chromosome alterations, which are not the result of chromosomal instability but which are specific alterations that are linked to tumour development and progression (Ehlers et al. 2008 ).
Chromosome alterations
In 1996, a strong association was observed between loss of one copy of chromosome 3 and the development of metastatic disease (Prescher et al. 1996) . Several studies had previously reported chromosome 3 aberrations in UM and had described the recurrent and non-random nature of these alterations (Horsman et al. 1990; Prescher et al. 1990 Prescher et al. , 1992 Sisley et al. 1990 Sisley et al. , 1992 Horsthemke et al. 1992; Horsman & White 1993; Wiltshire et al. 1993; Gordon et al. 1994; Speicher et al. 1994; White et al. 1996) . Prescher et al. (1996) detected monosomy 3 in 56% of a series of 54 UMs and reported a 50% metastasis rate at 3-years follow-up in patients whose tumour harboured this aberration, while none of the patients with a disomy 3 melanoma had developed metastatic disease. Subsequent studies in larger cohorts showed monosomy 3 in 25% to 65% of UMs and confirmed the strong association with metastatic disease (Table 1A) (Sisley et al. 1997; Scholes et al. 2003; Damato et al. 2007 Damato et al. , 2010 Shields et al. 2011; van den Bosch et al. 2012; Thomas et al. 2012; Ewens et al. 2013 Ewens et al. , 2014 Koopmans et al. 2014; Dogrus€ oz et al. 2017) .
Monosomy 3 is known to be associated with clinicopathologic features indicative of a poor prognosis, such as large tumour diameter, ciliary body involvement, epithelioid melanoma cytomorphology (Scholes et al. 2003; Damato et al. 2007; Shields et al. 2017) and inflammation (Maat et al. 2008; Bronkhorst et al. 2012) . Nevertheless, monosomy 3 is also predictive of metastatic death independent of clinicopathologic factors (Damato et al. 2007 ) and has been shown to be superior to clinicopathologic factors as a prognostic indicator (Prescher et al. 1996; McNamara et al. 1997; Kilic et al. 2006) . In UM metastases, the presence of monosomy 3 has been associated with decreased survival from the time of diagnosis of disseminated disease (Abdel-Rahman et al. 2012) .
Some studies proposed that complete monosomy 3 is more strongly correlated with metastasic risk than partial monosomy 3 (Abdel-Rahman et al. 2011a; Shields et al. 2011 ). However, when considering cases with borderline results as 'normal' and only defining tumours with definite loss of chromosome 3 as such, Damato and associates reported similar rates of metastatic death for cases with partial or total loss of chromosome 3 , which was corroborated in a study by Ewens et al. (2013) .
Another type of loss of heterozygosity (LOH) of chromosome 3, isodisomy 3 (White et al. 1996) , which occurs in 5% to 10% of cases, conveys a metastatic risk that is similar to monosomy 3 . Isodisomy is the presence of two identical copies of a chromosome, both from the same parent. This implies that the pathologic effect of monosomy 3 is not due to haploinsufficiency, but due to complete loss of various tumour suppressor proteins, presumably by mutations on certain loci on the remaining copy of chromosome 3. It is supposedly this abnormal copy that is duplicated in tumours with isodisomy 3 ). The way monosomy 3 affects tumour development and progression has not yet been elucidated. As monosomy 3 UMs exhibit a higher level of aneuploidy than disomy 3 tumours, it has been suggested that monosomy 3 leads to increased genomic instability (Ehlers et al. 2008) .
Another chromosome that is frequently altered in UM is chromosome 8 (Prescher et al. 1990; Sisley et al. 1990 Sisley et al. , 1992 Horsman & White 1993) . Gain of the long arm of chromosome 8 (8q), which often results from isochromosome formation, is associated with poor prognosis and occurs in 37% to 63% of primary UM (Sisley et al. 1997; Kilic et al. 2006; Damato et al. 2007 Damato et al. , 2010 van den Bosch et al. 2012; Ewens et al. 2013; Koopmans et al. 2014; Dogrus€ oz et al. 2017) . Isochromosome 8q leads to gain of material because it results in three copies of 8q while there is only one copy of 8p. An increasing dosage of 8q has been shown to convey an even greater risk of metastatic death (Sisley et al. 1997; Versluis et al. 2015) . Gain of 8q commonly accompanies monosomy 3 and the concomitant occurrence of these aberrations is associated with a higher risk of metastasis than either of the aberrations alone (Sisley et al. 1997; Damato et al. 2007 Damato et al. , 2010 Cassoux et al. 2014) . We corroborated this in a recently published study in collaboration with the Copenhagen University Hospital Rigshospitalet (Denmark), in which we reported on combining AJCC staging and chromosome 3 and 8q status to improve prognostication (Dogrus€ oz et al. 2017) . In the cohort of 470 UMs with known chromosome 3 and 8q status, tumours harbouring monosomy 3 as well as chromosome 8q gain showed an increased risk of metastatic death (Fig. 1) .
Although less frequently occurring than loss of chromosome 3 and gain of chromosome 8q, loss of the short arm of chromosome 1 (1p) is quite common in UM (19-34%) (Kilic et al. 2006; Damato et al. 2010; van den Bosch et al. 2012; Ewens et al. 2013; Koopmans et al. 2014) , especially in metastasizing tumours (33%) (Aalto et al. 2001) . In keeping with that finding, loss of 1p is associated with monosomy 3 (H€ oglund et al. 2004; H€ ausler et al. 2005; Damato et al. 2010 ) and the concurrent loss of 1p and chromosome 3 has been reported to be an independent predictor of decreased disease-free survival (Kilic et al. 2005) .
To the best of our knowledge, gain of 6p was the first chromosome aberration that was reported in UM (Griffin et al. 1988) . The loss of the long arm of chromosome 6 (6q) is more common in metastasizing than in non-metastasizing primary UM (Aalto et al. 2001) , while in contrast to all aforementioned chromosome alterations, gain of the short arm of chromosome 6 (6p) has a protective effect (White et al. 1998; Damato et al. , 2010 . However, tumours with a normal chromosome 3 status and normal chromosome 6p status show a better prognosis than those with 6p gain (Ehlers et al. 2008) . Between 18% and 54% of UM exhibit gain of chromosome 6p (Kilic et al. 2006; Damato et al. 2010; van den Bosch et al. 2012; Ewens et al. 2013; Koopmans et al. 2014) , which is almost mutually exclusive to monosomy 3, suggesting distinct evolutionary pathways of tumour development (Parrella et al. 1999; H€ oglund et al. 2004; Hughes et al. 2005) . Although chromosome 8q gain is related to monosomy 3, it also occurs in tumours with gain of 6p (Ehlers et al. 2008) . While it has been hypothesized that monosomy 3 is the first step in the malignant transformation of UM (Landreville et al. 2008) and that 8q gain occurs after monosomy 3 or 6p gain (Parrella et al. 1999; Ehlers et al. 2008 ), a recently published study reported monosomy 3 heterogeneity in tumours that are homogeneous for 8q gain; the authors therefore concluded that monosomy 3 is preceded by gain of 8q . A study by Singh et al. (2015) indicated that gain of the telomeric part of 8q has a central role in UM tumorigenesis and reported this aberration in 92% of their studied tumours. Their analysis showed that this aberration is followed by either gain of the centromeric 8q and loss of chromosome 3, or by gain of chromosome 6p, as well as 7q, 11p and 22q. 
Gene expression profiling
Since UM is characterized by nonrandom chromosome aberrations with distinct prognostic implications, it was anticipated that UM could be separated into prognostic groups based on gene expression profiling (GEP). In 2003, Tschentscher et al. (2003) performed unsupervised hierarchical cluster analysis of gene expression data on 20 primary tumours using a microarray gene chip of 12 500 probes and defined two distinct molecular classes, correlating with chromosome 3 status. Zuidervaart et al. (2003) , in an independent study, performed an mRNA expression array on 12 UM cell lines and identified four genes that were used on 19 primary UM samples to separate them into two groups, based on the expression of these genes. A subsequent study by Onken et al. (2004) in 40 primary UM used a microarray chip containing approximately 45 000 probes and confirmed the clustering of UM into two molecular groups. This study showed that the two observed specific gene expression profiles predicted survival. Class 1 tumours were found to correlate with a low risk of metastatic death with a 92-month survival rate of 95% as compared to 31% in class 2 UM (the high-risk tumours). In a subgroup analysis of 10 tumours, chromosome 6p gain was found in four of five class 1 tumours and in none of the class 2 tumours, while loss of chromosome 3 occurred in four of five class 2 cases and in none of the class 1 UMs. All class 2 tumours with loss of chromosome 3 also showed gain of chromosome 8q, which was found in only two class 1 UMs (Onken et al. 2004) .
Recently, class 1 tumours have been subdivided into class 1A (2% 5-year metastatic risk) and class 1B (21% 5-year metastatic risk) (Field & Harbour 2014) , based on the differential expression of the CDH1 and RAB31 genes . Class 2 tumours occur more frequently in older patients (Onken et al. 2004) and are related to monosomy 3 ), greater thickness, epithelioid cell type (Chappell et al. 2012) , extravascular matrix loops (Onken et al. 2005 ) and a higher proliferation rate (Ki-67 score) (Onken et al. 2010a) . Class 2 tumours have been subclustered into class 2A and class 2B. Class 2B cases harbour a loss of chromosome 8p that makes the tumours even more aggressive and results in an earlier onset of metastasis compared to class 2A tumours (Onken et al. 2008a) . Recently, expression of PRAME has been associated with increased metastatic risk in class 1 as well as class 2 tumours .
The association between GEP class and survival has been validated independently in several studies (van Gils et al. 2008; Petrausch et al. 2008; Chappell et al. 2012) . For clinical purposes, a practical 15-gene assay based on the 12 most highly discriminating genes and 3 control genes, which can be performed on small biopsied tumour samples, has been developed (Onken et al. 2010b) , and validated in a large multicenter study . It has been claimed that analysis of mRNA results in more accurate prognostication than evaluating clinicopathologic parameters or chromosome 3 status Onken et al. 2012) . However, similar to the original reports by Tschentscher et al. (2003) , Onken et al. (2004) , and van Gils et al. (2008) , the mRNA expression pattern corresponds very strongly with chromosome 3 status (van Essen et al. 2014 ). In accordance with earlier reports by Damato's group on combining clinical, histologic and genetic predictors to improve prognostication in UM (Damato et al. 2011; Eleuteri et al. 2012 ), a recent study by Harbour's group (Walter et al. 2016 ) and another independent study (Corrêa & Augsburger 2016) indicated that largest basal diameter provides prognostic information that is independent of GEP (see section Conclusions and future perspectives: improving genetic prognostication).
Gene mutations
Unlike cutaneous melanoma, UM does not harbour mutations in BRAF or NRAS genes (Mooy et al. 1991; Cruz et al. 2003; Rimoldi et al. 2003; Weber et al. 2003; Zuidervaart et al. 2005 ), but instead is characterized by mutations in the GNAQ gene (chromosome 9q) and its paralogue GNA11 (chromosome 19p); these genes encode alpha subunits of the heterotrimeric G proteins associated with the transmembrane G protein-coupled receptors (Onken et al. 2008b; Lamba et al. 2009; Van Raamsdonk et al. 2009 Shoushtari & Carvajal 2014) . Mutations in these genes are thought to result in the constitutive activation of the mitogen-activated protein kinase (MAPK) pathway and protein kinase C (PKC) pathway, which are involved in cell growth, cell proliferation, differentiation and apoptosis (Onken et al. 2008b; Van Raamsdonk et al. 2009 Ambrosini et al. 2013; Chen et al. 2014; Chen et al. 2017) . The MAPK pathway is activated in up to 90% of primary UM (Weber et al. 2003) , and mutations of GNAQ and GNA11 have been reported in 83% to 91% of primary UM, occurring in a mutually exclusive manner (Van Raamsdonk et al. 2010; Daniels et al. 2012; Koopmans et al. 2013 ). Mutations in GNAQ are reported in 25-50% of tumours, while GNA11-mutant cases account for 33-58% (Table 1B) (Van Raamsdonk et al. 2009 Daniels et al. 2012; Furney et al. 2013; Harbour et al. 2013; Koopmans et al. 2013; Martin et al. 2013; Dono et al. 2014; Ewens et al. 2014; Decatur et al. 2016; Moore et al. 2016; Yavuzyigitoglu et al. 2016) .
GNAQ and GNA11 mutations are considered to be initiating events in UM pathogenesis as they are present in the majority of UM, regardless of chromosome aberrations or GEP class, and are also found in benign melanocytic lesions such as blue nevi (Onken et al. 2008b; Van Raamsdonk et al. 2009 . Van Raamsdonk et al. (2010) found a mutation in either GNAQ or GNA11 in 61% of the 139 blue nevi they have tested and reported an 83% mutation frequency for GNAQ in 29 tested blue nevi in an earlier study (Van Raamsdonk et al. 2009 ). Although most studies could not find a correlation between GNAQ or GNA11 and survival (Bauer et al. 2009; Van Raamsdonk et al. 2010; Koopmans et al. 2013 ), a recent study by Griewank et al. (2014) reported a predominance of GNA11 mutations in UM metastases, and a poorer diseasespecific survival of GNA11-mutant tumours in a cohort of 30 UM patients with metastases. In 101 UMs treated by primary enucleation in the LUMC, we found monosomy 3 in 70% of GNA11-mutant UMs (n = 53) versus 48% in GNAQ-mutant UMs (n = 48) (Pearson's chi-squared test, p = 0.03) (M Dogrus€ oz, unpublished data). Although we noticed a trend towards worse survival for GNA11-mutant tumours compared to GNAQ-mutant cases, this difference was not significant (log-rank test, p = 0.27) (M Dogrus€ oz, unpublished data).
As mentioned above, the strong correlation between LOH of chromosome 3 and an adverse prognosis raises the suspicion that loss of function of tumour suppressor genes on chromosome 3 may result in a malignant phenotype. Early efforts to identify the critical region of chromosome 3 yielded varying results (Blasi et al. 1999; Tschentscher et al. 2001; Parrella et al. 2003) . Blasi et al. (1999) found a translocation involving chromosome region 3p13 as the only clinical aberration in a primary UM cell culture and suggested that this region could harbour a pathogenically relevant tumour suppressor gene. Tschentscher et al. (2001) investigated partial deletions of chromosome 3 and found two regions (3q24-26 and 3p25) that were frequently lost. A study by Parrella et al. (2003) identified the same region (3p25.1-25.2), and overlapping results were reported by Cross et al. (2006) and van Gils et al. (2008) , who also speculated on a segment (3p12-3p14) similar to the one addressed earlier by Blasi et al. (1999) .
In 2010, inactivating hemizygous somatic mutations of the BAP1 (BRCA1-associated protein-1) gene on chromosome 3p21.1 were identified in 47% of 57 UM cases. BAP1 mutation was found in most metastasizing UMs, occurring in 84% (26/31) of class 2 tumours and in only 4% (1/26) of class 1 cases (Harbour et al. 2010) . Subsequent studies showed that inactivating mutations of BAP1 occur in 32-58% of primary UM (Furney et al. 2013; Harbour et al. 2013; Dono et al. 2014; Ewens et al. 2014; Koopmans et al. 2014; Decatur et al. 2016; Moore et al. 2016; van de Nes et al. 2016; Yavuzyigitoglu et al. 2016) . Mutation of BAP1 is also strongly correlated with chromosome 3 status (Robertson et al. 2017) , occurring in 89% of monosomy 3 tumours and in none of the disomy 3 tumours, in a cohort of 66 UMs (van de Nes et al. 2016) .
Loss of BAP1 gene expression has been shown to correlate well with the lack of BAP1 protein expression, which has been proposed as a clinically valuable prognostic tool (Shah et al. 2013; van Essen et al. 2014; Kalirai et al. 2014; Koopmans et al. 2014; van de Nes et al. 2016) . Metastases arise when there is a combination of loss of one copy of chromosome 3 and a mutation in the BAP1 gene on the other copy, resulting in the loss of expression of BAP1 (van Essen et al. 2014; Koopmans et al. 2014) .
The BAP1 protein is an ubiquitin carboxyterminal enzyme that affects the activity of other proteins through deubiquitination. For example, it regulates gene expression epigenetically by removing ubiquitin molecules from histone H2A. It has been demonstrated that loss of BAP1 function leads to the loss of the melanocytic cell phenotype and loss of differentiation in UM (Matatall et al. 2013) .
Germline mutations in BAP1 (Abdel-Rahman et al. 2011b ; Maerker et al. 2014 ) have been identified in 2-3% of UM patients (Aoude et al. 2013; Gupta et al. 2015; Turunen et al. 2016) . These patients tend to have a family history of UM. A recent study reported BAP1 germline mutations in approximately 20% of familial cases of UM (Rai et al. 2017) . Patients with BAP1 germline mutations have larger tumours, with more common ciliary body involvement, both of which are related to a higher risk of metastasis (Gupta et al. 2015) . These mutations may be present in UM occurring at a younger age (Cebulla et al. 2015) . In addition, patients with germline BAP1 mutations are at higher risk of other cancers such as lung adenocarcinoma, renal cell carcinoma, meningioma and malignant mesothelioma (Abdel-Rahman et al. 2011b; Testa et al. 2011; Popova et al. 2013; Pilarski et al. 2014) , prompting the need for physicians to recognize familial cases of UM and to identify patients with germline BAP1 mutations.
In contrast to BAP1, mutations in the SF3B1 (splicing factor 3 subunit B1) gene on chromosome 2q are associated with favourable prognostic parameters such as younger age at diagnosis and fewer epithelioid cells, while being inversely associated with adverse prognostic features such as monosomy 3 and the class 2 gene expression profile (Martin et al. 2013) . Patients with mutations in this gene account for 10% to 24% of UM cases (Furney et al. 2013; Harbour et al. 2013; Martin et al. 2013; Dono et al. 2014; Ewens et al. 2014; Decatur et al. 2016; Moore et al. 2016; Yavuzyigitoglu et al. 2016) . In a study by Furney et al. (2013) , patients with SF3B1 mutations showed a better prognosis than patients with SF3B1-wildtype tumours, while in another study significance could not be reached (Martin et al. 2013) and in a study with a relatively short follow-up (48 months), no association with metastatic disease was reported (Ewens et al. 2014) . In a long-term study by Yavuzyigitoglu et al. using whole-exome sequencing (WES), an association of mutated SF3B1 with favourable prognosis was observed in the overall group (n = 133, 32 SF3B1-mutant) during the first few years of follow-up; however, this difference was less evident at longer follow-up since patients with SF3B1 were noticed to develop metastases at a later stage. Within the disomy 3 cohort, patients with SF3B1 mutations had an increased metastasic risk when compared to patients without this mutation and developed metastases at a median follow-up of 8.2 years. SF3B1 mutation was therefore correlated with lateonset metastasis and was the only parameter independently associated with worse survival in disomy 3 tumours in the multivariate analysis. Most (11/14) disomy 3 patients who developed metastases had an SF3B1 mutation, while BAP1 mutations were found in two other disomy 3 patients who developed metastases (Yavuzyigitoglu et al. 2016 ). These mutations were missense mutations, and the tumours stained positively for BAP1 using immunohistochemistry. Although it may be assumed that a non-functional protein is produced, this should be validated by functional assays.
Mutations in the EIF1AX (eukaryotic translation initiation factor 1A, Xlinked) gene on chromosome Xp are found in 8% to 21% of primary UMs and are associated with a decreased risk of metastasis (Furney et al. 2013; Martin et al. 2013; Dono et al. 2014; Ewens et al. 2014; Decatur et al. 2016; Moore et al. 2016; Yavuzyigitoglu et al. 2016) . Ewens et al. (2014) reported a 10-fold lower metastasic risk for disomy 3/BAP1-wild type/ EIF1AX-mutant tumours, when compared to disomy 3/BAP1-wild type/ EIF1AX-wild type cases. The association of EIF1AX mutations and a favourable clinical outcome was confirmed in two recently published studies Yavuzyigitoglu et al. 2016) . Together, these reports show that mutations in BAP1, SF3B1 and EIF1AX occur in a mutually exclusive manner, which has been underlined by a study that reported on the results of whole-genome sequencing (WGS) in 33 samples (Royer-Bertrand et al. 2016) . Moreover, mutations in these three genes are associated with differing risks of developing metastasis. Tumours with BAP1 mutations show a high and early metastatic risk, whereas tumours with mutated SF3B1 are associated with late-onset metastasis and EIF1AX-mutant tumours have a very low metastatic risk (Yavuzyigitoglu et al. 2016 ).
Genetic Tests
Diverse genetic techniques, such as karyotyping, fluorescence in situ hybridization (FISH), multiplex ligation-dependent probe amplification (MLPA), array-based comparative genomic hybridization (aCGH), single-nucleotide polymorphism (SNP) assay and GEP, are commonly utilized to determine genomic tumour characteristics with prognostic value in UM. Relevant aspects to take into consideration with regard to the application of a certain test are the type of tumour specimen (fresh tumour tissue/frozen/ formalin-fixed paraffin embedded), the available type of genetic material from the tumour specimen (DNA/RNA), the prognostic accuracy of the test, and the costs of the test. In this section, we briefly discuss the most important tests that can be utilized for genetic prognostication in UM and address their respective advantages and disadvantages (Table 2) .
Initial studies reporting on the prognostic value of aberrations in chromosomes 3 and 8 (Horsman et al. 1990; Prescher et al. 1990 Prescher et al. , 1996 Sisley et al. 1990 ) used karyotyping in short-term cultured UM cells, which was also utilized in later studies to further characterize UM cytogenetically (Kilic et al. 2006; Dogrus€ oz et al. 2015) . The advantage of karyotyping is that it provides information on all chromosomes in a single assay and allows the identification of structural and balanced chromosome abnormalities, in addition to numerical changes. However, tumour specimens must be fresh since viable dividing cells are required. Furthermore, this method is labourintensive and has to be performed by an experienced cytogeneticist. Another disadvantage of karyotyping is that it can only reliably detect gross aberrations due to its overall low resolution of approximately 5 to 10 Mega base pairs (Mbp) (Fletcher et al. 1991; Bridge & Sandberg 2000; Bridge 2008 ). Kilic et al. (2006) have reported a 100% 10-year mortality in patients with loss of chromosome 3p detected by karyotyping, and a 30% mortality rate in patients without this aberration. The relatively high percentage of mortality in patients without detected loss of chromosome 3p may be explained by the low sensitivity of karyotyping in detecting LOH in cases of isodisomy 3 (copy-neutral LOH) (White et al. 1996) .
Another approach to chromosomal testing is FISH, which can be performed on aged, frozen and paraffin-embedded specimens as well as fresh samples. Fluorescence in situ hybridization (FISH) uses a technique where a specific coloured probe is used that binds to a specific chromosome site. Fluorescence in situ hybridization (FISH) can be performed on tissue sections as well as isolated nuclei (Maat et al. 2007) . Two advantages of FISH over karyotyping are, first, that it does not require the presence of viable dividing cells to yield a successful result and, second, it does not have to be performed by an experienced cytogeneticist (Bridge 2008) . Fluorescence in situ hybridization (FISH) has been shown to be a reliable technique for detecting chromosome 3 and 8 aberrations (Patel et al. 2001 ) and has been used, alone or in combination with conventional karyotyping, for the assessment of the chromosome status of UM (McNamara et al. 1997; Sisley et al. 1997; Damato et al. 2007; Maat et al. 2007; Midena et al. 2008; Bronkhorst et al. 2011; Dogrus€ oz et al. 2015) .
Limitations of FISH are that it only allows evaluation of alterations in the targeted (region of) a chromosome (Eastmond et al. 1995) and its inability to detect isodisomy of chromosome 3 and structural abnormalities such as partial deletions (in particular if only centromeric probes are used) (Damato et al. 2007; ). An example of this is provided by Lake et al. (2010) in metastasizing UM, where MLPA identified two cases with multiple deletions in 3p and 3q, which were previously missed by FISH. Although it has been reported that FISH and MLPA have similar predictive powers (Vaarwater et al. 2012 ), Damato and associates, have shown that MLPA is more sensitive than FISH in detecting partial deletions of chromosome 3 Russo et al. 2012) , also validating the use of this technique for prognostication in UM in a large cohort of 452 choroidal melanomas ). Multiplex ligation-dependent probe amplification (MLPA) can be performed on smaller samples than FISH, which makes it suitable for use in biopsy material . Although MLPA can be used on formalin-fixed tumour specimens, the use of fresh or snap-frozen material is preferred (Lake et al. 2012 ). However, similar to karyotyping and FISH (Maat et al. 2007; Mensink et al. 2009; Schoenfield et al. 2009; Bronkhorst et al. 2011) , MLPA is prone to sampling errors caused by tumour heterogeneity Dopierala et al. 2010) . The effect of sampling errors on the predictive value of these tests was not specifically determined.
Another technique used for genetic testing in UM is aCGH (Trolet et al. 2009; Cassoux et al. 2014; Hammond et al. 2015) . In aCGH, tumour DNA and reference DNA are labelled differently and hybridized with cloned DNA fragments (AE100-200 kb) of which the exact chromosome location is known (Oostlander et al. 2004; Pinkel & Albertson 2005) . Array-based comparative genomic hybridization (aCGH) provides genome-wide information on copy-number variations and can detect smaller aberrations than karyotyping and FISH (de Ravel et al. 2007; Hammond et al. 2015) . However, as with karyotyping, FISH and MLPA, aCGH is unable to detect copy-neutral LOH, and therefore cannot identify isodisomy 3.
A more modern technique is the use of SNP arrays, in which variations of single nucleotides are evaluated. A major advantage of SNP is its ability to detect isodisomy 3, as it can distinguish the two copies of chromosomes inherited from each parent. In a study by Onken et al. (2007) , SNP was more accurate than FISH and aCGH in detecting LOH of chromosome 3 due to its ability to identify isodisomy 3. Another technique that can be utilized to detect isodisomy 3 is microsatellite analysis (MSA), which evaluates the presence of informative microsatellite marker regions of repetitive DNA on chromosomes. However, this technique is also susceptible to sampling error resulting from tumour heterogeneity (Tschentscher et al. 2000) .
Recently, WES and WGS have been applied for research purposes to evaluate the genetic landscape of UM (Royer-Bertrand et al. 2016; Yavuzyigitoglu et al. 2016 ). Whole-exome sequencing (WES) sequences all exons of the genome, thereby identifying genetic variants that alter protein sequences, while WGS also sequences the non-coding regions. Although WGS provides more information than WES, it has higher costs and is more time-consuming. However, costs keep decreasing, probably soon allowing WGS for a fair cost.
In contrast to the above-mentioned genetic tests, which analyse DNA, GEP evaluates mRNA expression to stratify tumours into two main prognostic classes, class 1 and class 2 (Onken et al. 2004 ). In the initial paper correlating Onken et al. (2004) stated that this molecular classification may potentially be superior to chromosome analysis in predicting high-risk cases. However, the studies showing a higher accuracy of GEP were performed with relatively few patients, and FISH and aCGH were used instead of more reliable chromosome tests to detect chromosome copy-number variations. As mentioned earlier, these techniques are unable to detect isodisomy of chromosome 3, which is related to the development of metastatic disease ). Certain chromosome aberrations correspond to the GEP classes, and it has been shown that combining prognostic information provided by different chromosomes increases the predictive accuracy of chromosome testing (Sisley et al. 1997; Damato et al. 2007 Damato et al. , 2010 Trolet et al. 2009; Cassoux et al. 2014) .
Although GEP is more costly than tests based on chromosome analysis, one of the advantages of GEP over chromosome testing has been proposed to be its insensitivity for sampling errors because of tumour heterogeneity (Onken et al. 2010b) . This is supposedly due to the fact that it evaluates the tumour environment, which is less variable across the tumour than the cytogenetic markers. Nevertheless, a recently published study by Augsburger et al. (2015) evaluating the GEP classification of biopsy samples from different sites within a tumour, reported a discordance rate of 11%. Although GEP is able to provide prognostic information even in very small samples (Correa & Augsburger 2014) , Augsburger et al. (2015) found that discordant GEP results occur most frequently (24%) in small tumours (thickness <3.5 mm). To decrease the risk of misclassification, the Collaborative Ocular Oncology Group (COOG) has recommended taking several samples if the tumour consists of morphologically different areas ). In accordance with this recommendation, a recently published case report showed discordant GEP results of samples with different histopathologic features (Miller et al. 2017) .
Clinical Aspects of Genetic Prognostication
Genetic testing for prognostication in UM is now applied in many ophthalmic oncology centres. The clinical application of genetic testing has raised certain issues, which we highlight in this section. Below we discuss implications of genetic prognostication for follow-up and therapy of patients. We also address clinical issues regarding the use of biopsy material and the application of genetic testing in irradiated tumours, highlight statistical issues considering the interpretation of the results of genetic prognostication, and discuss the psychological effects of genetic prognostication on patients.
Implications for follow-up and therapy
Genetic prognostication will play an important role in the stratification of patients in clinical trials in order to evaluate the efficacy of novel adjuvant treatments. It allows the identification of high-risk patients who may benefit the most from adjuvant therapies and thereby guides enrolment of patients in Certain chromosome aberrations correspond to the GEP classes, clinical trials to test therapies targeting micrometastases. Prognostic stratification allows clinicians to taylor followup measures according to metastatic risk: those with a low-risk can be spared from follow-up examinations, saving costs, while more intensive surveillance can be offered for highrisk patients. However, there is a lack of consensus regarding the type and frequency of systemic screening (Gombos et al. 2004) , and the possible survival benefit of earlier detection of clinical metastases for the individual patient has been questioned as no effective treatment for metastatic UM yet exists.
In a study by Kim et al. (2010) the median survival after diagnosis of primary UM of 90 patients with metastatic UM detected by surveillance was only 4.5 months longer than the survival of 259 patients who were diagnosed with metastatic UM after they developed symptoms. The percentage of patients receiving treatment for UM metastases and the treatment type was comparable between the groups. The authors concluded that the difference in survival was due to lead-time bias. Similarly, an earlier study reported a longer survival after detection of metastases (8.9 versus 4.3 months) in patients who had undergone surveillance examinations (Eskelin et al. 2003 ). However, the survival time after diagnosis of the primary tumour was comparable. More recent studies evaluating the effects of novel treatment options have reported prolonged survival in patients whose metastases were detected earlier (Luke et al. 2013; Carvajal et al. 2014) . Nevertheless, no clear survival benefit from screening for metastases was reported in a literature review by Augsburger et al. (2011) , while a recently published review concluded that adjuvant therapy has not been shown to improve survival in UM (Choudhary et al. 2015) .
Studies on the analysis of genetic differences between high-risk and lowrisk tumours have resulted in an enhanced understanding of the pathogenesis of UM. The discovery of GNAQ/GNA11 and BAP1 mutations has contributed to the unravelling of the molecular landscape of UM and provided opportunities for targeted therapy of metastatic disease (Patel et al. 2011; Landreville et al. 2012; Chen et al. 2014) . Progress in the molecular characterization of UM may not only improve prognostication but may also contribute to the development of targeted therapy and may in the near future even allow for individualized treatment based on mutational analysis of the tumour.
Genetic testing in biopsies
Uveal melanomas (UMS) treated by enucleation provide adequate tumour samples for genetic testing. Since the entire tumour is available, samples from different parts of the tumour can be sent in for genetic analysis. However, most UMs are currently treated by globe-preserving techniques such as plaque radiotherapy and proton beam irradiation while enucleation is reserved for larger tumours (Tarlan & Kiratli 2016) . In tumours treated by eye-conserving methods, biopsies may be taken to obtain tumour material for genetic prognostication. Although there is a risk of localized bleeding, vitreous haemorrhage, retinal detachment and tumour seeding after a tumour biopsy, these risks are small and fine-needle aspiration biopsy (FNAB) is considered a safe procedure (Midena et al. 2006 (Midena et al. , 2008 Shields et al. 2011; McCannel et al. 2012; Kim et al. 2017) .
Tumour size may be a limiting factor as smaller tumour volume may make it difficult to acquire sufficient material for testing. Even in enucleated cases, larger tumour size was found to be correlated with a higher success rate of FISH in 213 primarily enucleated tumours (Dogrus€ oz et al. 2015) . McCannel et al. (2012) performed transscleral FNAB in 170 cases and reported that sufficient material for FISH was obtained in 91% of tumours with a thickness over 5 mm, while this percentage was only 53% for tumours less than 3 mm thick. In a study of FNAB performed in a cohort of 150 UM, Singh et al. (2016) found that a sufficient yield of tumour material was related to tumour size, with more successful tests in larger tumours (basal diameter >5.0 mm, height >2.5 mm), as well as to the biopsy approach (success rates, transcorneal: 100%, transscleral: 96%, transvitreal: 86%). In contrast, Shields et al. (2007) determined the chromosome 3 status in FNAB specimens by analysing microsatellite markers and found that a transvitreal approach more often (97%, 31/32) yielded sufficient material than a transscleral approach (67%, 16/24). However, a study in 38 patients showed comparable results for transvitreal and transscleral FNAB approaches, with sufficient material for cytopathological analysis in 71% and 66% of tumours, respectively (Chang & McCannel 2014) . Recent improvements in surgical techniques and laboratory methods increased the success rate of genetic testing in biopsied samples as shown by the group of Coupland (Angi et al. 2017) . They analysed their samples biopsied between 2011 and 2013 and noticed an increase in success rate from 79% to 93%.
The type of needle may also influence tissue yield, which is affected by the diameter of the needle bore so that a larger specimen is obtained by FNAB with 25-gauge needles than with 27-gauge or 30-gauge needles (Bagger et al. 2015) . In a study of 18 UM cases, transscleral FNAB using a 30-gauge needle yielded sufficient material for FISH for chromosome 3 testing in 50% of cases (Young et al. 2007 ). Midena et al. (2006) obtained adequate material for chromosome 3 testing using FISH with a 25-gauge transscleral FNAB in 7 of 8 cases and in 81% of tumours in a subsequent larger cohort (n = 32) (Midena et al. 2008) .
As already indicated, the biopsy technique may influence the size of the specimen and the success rate. Transretinal biopsies using a 25-gauge vitrector have been shown to harvest larger tissue samples when compared to FNABs, improving the chance of obtaining adequate tumour samples for histologic examination and cytogenetic analysis (Sen et al. 2006; Bagger et al. 2015) . Bagger et al. (2015) have shown that the theoretical tissue yield of a 25-gauge vitrector-based biopsy is higher than the tissue yield of FNABs using 25-gauge, 27-gauge and 30-gauge needles. They have reported a low risk of complications for this procedure (Bagger et al. 2013) .
The question has arisen as to whether a single biopsy is truly representative of the entire tumour. As mentioned previously, genetic heterogeneity in UM has been reported ) and may cause genetic misclassification of tumours when genetic testing is performed on biopsies. Naus et al. (2002) reported the application of FISH in FNABs to be a reliable method for assessing chromosome 3 and 8q status in 40 UM samples; however, other studies reported heterogeneity for chromosome 3 as determined by FISH in 14% (Maat et al. 2007 ) to 32% of cases (Sandinha et al. 2006) . Regarding MLPA for chromosome 3 status, interpretation of results was complicated by genetic heterogeneity in 13% of cases . In contrast, in a recent study by Coupland et al. (2015) who performed MLPA (n = 14) and MSA (n = 14) on 28 biopsies and matching tumour sections, concordant results for chromosome 3 status were reported in all cases. As mentioned above, it has been suggested that because GEP evaluates the tumour microenvironment, which is assumed to be less variable across the tumour, one might expect that GEP is less prone to sampling errors caused by genetic heterogeneity. Nevertheless, a discordance rate of 11% was reported recently by Augsburger et al. (2015) who compared two random samples from the same tumour. To increase the chance of obtaining sufficient tumour material and to minimize the risk of genetic misclassification of the tumour, various authors have proposed performing vitrector-based biopsies or taking multiple FNAB samples (Bagger et al. 2015) .
Genetic testing in irradiated tumours
Most UM patients are treated by irradiation, with a biopsy being performed prior to radiotherapy. However, in some centres, biopsies are not taken routinely and genetic testing is performed only on secondarily enucleated tumours in which since radiotherapy failed. Alternatively, tumour material for genetic testing may be obtained after endoresection of large melanomas that were irradiated (Bechrakis & Foerster 2006) . However, as the radiobiological effects of irradiation on tumour cells results in necrosis and fibrosis (Messmer et al. 1992; Saornil et al. 1992 Saornil et al. , 1997 Gragoudas et al. 1993; Schilling et al. 1994; Avery et al. 2008) , the probability of successfully performing a genetic test on these tumours is questioned. We recently published a study evaluating success rates of karyotyping and FISH and found that both tests are more likely to be successful in primarily enucleated tumours (n = 291) than in tumours enucleated after radiotherapy (n = 36, 28 Ruthenium-106 brachytherapy) (Dogrus€ oz et al. 2015) . Karyotyping was successful in 79% of primarily enucleated cases, while this was the case in only 25% of the previously irradiated tumours. Fluorescence in situ (FISH) hybridization was performed when karyotyping had not shown monosomy 3 or had failed and was more often than karyotyping successful in irradiated cases (17/35, 49%) (Table 3) . Horsman & White (1993) successfully performed karyotyping in 20 of 23 (87%) primarily enucleated tumours and 7 of 12 (58%) previously irradiated tumours (gold plaque brachytherapy). The greater success rate when compared to our cohort may be due to a difference in the time interval between radiotherapy and time of enucleation, since more necrosis and fibrosis has been reported when the time interval between irradiation and enucleation was larger (Gragoudas et al. 1993; Schilling et al. 1994 ).
Secondly, not only the time interval but also the reason for the secondary enucleation may influence the success rate of genetic tests. In our study, we found that, although not significantly different, karyotyping as well as FISH tended to be more often successful in irradiated tumours that were enucleated because of tumour recurrence, compared to enucleations due to tumour non-responsiveness or radiation-related complications (Dogrus€ oz et al. 2015) . The fact that the recurrent tumour is unaffected by radiobiological damage inflicted by irradiation may explain this difference.
Thirdly, the success of genetic typing in irradiated tumours may also depend on the type of test. Wackernagel et al. (2013) performed aCGH in 15 irradiated UMs (5 Ruthenium-106 brachytherapy, 10 Gamma-Knife radiotherapy) and obtained successful results in all cases, while Gold et al. (2014) successfully performed GEP in 3 irradiated cases (2 Iodine-125 brachytherapy, 1 proton beam irradiation). Coupland et al. (2015) successfully determined the genetic status of eight previously irradiated (5 Ruthenium-106 brachytherapy, 3 proton beam irradiation) solid (enucleation/endoresection) specimens using MLPA and in one enucleated specimen that was previously treated with proton beam irradiation using MSA. However, these three studies were performed in small cohorts of only a few cases.
Another important issue regarding genetic testing after irradiation is whether the results are representative of the primary genetic status of the tumour, as radiotherapy may cause genetic alterations. Hussain et al. (2016) performed survival analysis in 102 patients in whom the genetic status of the tumour was determined by MLPA/MSA on biopsies taken after proton beam irradiation. They found a metastatic death rate of 0% in 63 patients with disomy 3, while 35% of 39 monosomy 3 patients died of UM metastases. This suggests that genetic testing by MLPA/MSA after proton beam irradiation is reliable and accurately predicts disease outcome. The fact that biopsies were taken less than a month after proton beam irradiation may have contributed to their accurate testing results, as the time between irradiation and sampling may affect the success of genetic testing. Coupland et al. (2015) reported concordant results for chromosome 3 status when comparing the biopsy specimens with the enucleated specimens in 4 tumours that were treated by Ruthenium-106 brachytherapy and secondarily enucleated due to tumour recurrence. Wackernagel et al. (2013) found concordant results for chromosome 3 and 8 status determined by aCGH pre-radiotherapy and post-radiotherapy in five cases with a median time interval of 76 days between radiotherapy and genetic analysis. Further studies evaluating genetic testing pre-radiotherapy and postradiotherapy in larger cohorts with longer follow-up are necessary to determine the reliability of genetic tests after radiotherapy. Because of the lack of validation in post-radiotherapy tumours and the potential radiobiological effects of irradiation on the genomics of the tumour, irradiated samples have been considered ineligible for genetic testing using the DecisionDx-UM test (Plasseraud et al. 2016) .
Statistical considerations
Prognostic tools must take account of lead-time bias, competing risks, bias caused by missing data, loss of precision arising from categorization of continuous data, and other factors. For example, with respect to lead-time bias, larger tumours are associated with a shorter life expectancy partly because they have been growing and metastasizing for a longer time (Damato et al. 2011) . As for competing risks, the censoring (i.e. exclusion from analysis) of patients dying of unrelated disease may exaggerate the apparent metastatic mortality (Kujala et al. 2003) . For this reason, it is necessary to take into account the life expectancy of the general population, matched by age and sex (Damato et al. 2011) . Bias may also arise if nonrandom missing data is simply excluded, which is why some statistical models estimate the likely values of missing data according to other prognostic factors (Eleuteri et al. 2012) .
Loss of precision occurs when continuous data are categorized into groups so that, for example, an 0.1 mm difference in tumour diameter results in a great adjustment of survival probability.
Not all factors associated with mortality are useful for prognostication so that a multivariable analysis is necessary to determine which factors to include in the statistical model (Damato et al. 2008a; Eleuteri et al. 2012) . The sample size and the number of events (i.e. deaths) should be large enough for the model to have adequate statistical power. : indicates a rounded value or estimation as in the respective studies the time periods were mentioned as days or weeks.
To ensure that the prognostic tool is relevant to patients who were not included in its development, the statistical model should be evaluated on a test dataset that is separate from the training dataset, unless methods such as bootstrapping are used. Every prognostic tool should ideally be validated externally by different centres, which should ensure that tumour diameter and thickness are measured in a standardized manner and that structures such as ciliary body are defined consistently (DeParis et al. 2016) .
Genetic tumour type indicates whether or not the tumour has metastatic potential. If it does, then factors such as tumour size and mitotic count may indicate the likely survival time (Damato et al. 2008a ). If genetic studies suggest that the tumour has no metastatic potential, then anatomic and histological predictors should in theory not influence the prognosis; however, these biomarkers may sometimes cast doubt on a genetic test result (e.g. ostensible disomy 3 in a large tumour with ciliary body involvement, extraocular spread, epithelioid cells, closed loops and a high mitotic count).
Psychological aspects of genetic prognostication
Most ocular oncology centres offer UM patients genetic testing for prognostication. As an effective treatment for UM metastases is lacking, the main benefits of genetic prognostication for the patient are reassurance or lifeplanning. On the other hand, genetic testing for prognostication may have negative psychological consequences.
One can expect patients with a poor prognosis to experience psychological distress and regret their decision to get informed about their prognosis.
In a study in 298 UM patients, 97% accepted genetic prognostication and none of the patients regretted their decision to have testing (Cook et al. 2009 ). Patients reported that they gained a sense of control, which was linked to the hope that screening and early treatment would improve their survival. The authors had the impression that patients with a favourable prognosis benefitted the most. In another study, 36 of the 38 patients who received a prognostic test stated that they wanted to know the results, which to the authors indicated no obvious regret of the decision to undergo testing (Beran et al. 2009 ). The majority of patients (58%, n = 14 of 24) who received a conclusive result (monosomy 3/disomy 3) perceived prognostic testing as useful. However, disomy 3 patients more often found testing useful than monosomy 3 patients (69%, 9 of 13 versus 46%, 5 of 11, respectively). Disomy 3 and monosomy 3 patients perceived genetic testing as useful for different reasons: patients with a disomy 3 tumour indicated that the result provided relief/ hope, while patients with a monosomy 3 tumour generally stated that the genetic testing result inspired them emotionally and/or gave a reason to prepare for a shortened life. When assessing depressive symptoms and quality of life (mental/physical), the authors did not find significant differences between patients who received prognostic testing versus those who did not undergo testing, nor between monosomy 3 and disomy 3 patients. Similarly, Hope-Stone et al. (2015) did not find differences in experiences of uncertainty between patients who received an adverse prognosis and those having a favourable prognosis. The authors concluded that a good prognostic result does not necessarily relieve feelings of uncertainty.
In a recently published longitudinal study of 96 patients, depression, anxiety and decision regret prior to prognostication and at 3 and 12 months afterwards was assessed (Schuermeyer et al. 2016) . In contrast to the aforementioned studies, the authors reported decision regret in 10% and symptoms of depression in 9% of their patients at 12-months follow-up. Decision regret was not correlated with an unfavourable prognosis but was associated with depression, which may make patients question their decisions.
Conclusions and Future Perspectives: Improving Genetic Prognostication
Since the identification of monosomy 3 as a prognostic marker (Prescher et al. 1996) , using karyotyping, considerable progress has been made in the genetic prognostication of UM. New genetic markers have been identified, which, besides being used as prognostic indicators, have also enhanced our understanding of the pathogenesis of UM. The genes that initiate tumour formation and induce metastasis have been identified, which also resulted in the discovery of new targets for therapy. Assessment of the applicability of genetic tests in specific types of tumour specimens such as biopsy samples and irradiated tumours have expanded the group of tumours in which genetic testing for prognostication is possible. However, more research is necessary to determine which biopsy type and approach yields the best success rate with respect to genetic testing and prognostication. Also more studies need to be conducted to validate various genetic tests in irradiated tumours.
The field of prognostication in UM is a rapidly advancing one. Although chromosome status and GEP are shown to be accurate methods for prognostication, both carry a risk of tumour misclassification. Recent discoveries of specific gene mutations have made further risk stratification possible and helped to explain exceptional cases. Combining genetic prognostic measures with other tumour features and patient demographics clearly enhances prognostic accuracy. Multiplex ligation-dependent probe amplification (MLPA) for chromosome 3 has been shown to have increased accuracy when combined with information on the status of chromosome 8q as well as tumour diameter and histologic parameters characteristic of high-grade malignancy ). Damato and associates have created the Liverpool Uveal Melanoma Prognosticator Online (LUMPO) tool, which takes into account age, sex, chromosome 3 status, tumour size, tumour location, extraocular extension, cell type, presence of extracellular closed-loop matrices and mitotic count to estimate the survival probability for an individual patient (Damato et al. 2011; Eleuteri et al. 2012; DeParis et al. 2016 ). This tool has been used effectively to detect patients with a predicted 5-year mortality of at least 50% for inclusion in a prospective study evaluating metastasis screening by MRI in 188 high-risk cases (Marshall et al. 2013) .
Similar to the work of Damato and colleagues, combining genetic alterations with the AJCC stage, which is based on tumour size, ciliary body involvement and extraocular extension has been proposed as a means of enhancing prognostic accuracy (Kivel€ a & Kujala 2013) . We have expanded a prior study (Bagger et al. 2014) by combining data from our centre with their data (the Copenhagen University Rigshospitalet, Denmark) and we have demonstrated that the prognostic values of chromosome 3 and 8q status as well as the AJCC stage are enhanced when these prognostic parameters are applied together (Dogrus€ oz et al. 2017) . We have shown that adding information on the AJCC stage improves the prognostic value of chromosome 3 and 8q status (Fig. 2) . As chromosome 3 status corresponds closely to the GEP classes, it is expected that combining AJCC staging with GEP would enhance prognostication. In line with these findings, two recently published studies have reported that the tumour diameter has prognostic significance that is independent of GEP class (Corrêa & Augsburger 2016; Walter et al. 2016) .
Further stratification of risk estimates provided by genetic parameters may also be possible by combining information of several genetic determinants. Combining chromosome status with specific mutations such as BAP1/SF3B1/EIF1AX mutations also improves prognostic accuracy (Ewens et al. 2014; Decatur et al. 2016; Yavuzyigitoglu et al. 2016) , and recently PRAME has helped to stratify metastatic risk in GEP class 1 as well as class 2 tumours .
These recent findings indicate that genetic prognostication in UM is an advancing field in which continued research is expected to further enhance prognostic accuracy, improve patient counselling, planning of follow-up, and trial enrolment, and contribute to the identification of new therapeutic targets. 
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